RECEIVED CENTRAL FAX CENTER

NOV 0 9 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.

10/689,388

Applicants

Michael Philip Clark et al.

Filed

October 20, 2003

Title

6,7-Dihydro-5-H-pyrazolol[1,2-a]pyrazol-1-ones

Which Provide Analgesia

TC/A.U.

1624

Examiner

Thomas C. McKenzie

Conf. No.

4154

Docket No.

8717MR2

Customer No.

27752

TERMINAL DISCLAIMER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Petitioner, The Procter & Gamble Company, is the owner of the entire right, title and interest in the above-identified application (the assignment recorded on January 29, 2004 at reel 014288, frame 0426). Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §154 to §156 and §173 as presently shortened by any terminal disclaimer, of prior Patent Nos. 6,730,668 B2, issued May 4, 2004 (the assignment recorded on 11/21/2002 at reel 013260, frame 0781); 6,849,627, issued February 1, 2005 (the assignment recorded on 7/17/2003 at reel 01385, frame 0937); and 6,960,593 B2, issued November 1, 2005 (the assignment recorded on June 22, 2005 at reel 016385, frame 0437). The evidentiary documents for the assignments have been reviewed, and petitioner certifies that to the best of petitioner's knowledge and belief, title is in the assignee to take this action. Petitioner hereby agrees that any patents so granted on the above-identified application shall be enforceable only for and during such period that it and U.S. Patent Nos. 6,730,668 B2, 6,849,627 and 6,960,593 B2 are commonly owned.

This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the above-identified application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to §156 and §173 of the prior patents, as presently shortened by any terminal disclaimer, in the event that they later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The undersigned is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Authorization is given to charge Deposit Account No. 16-2480 for the fee required under 37 C.F.R. §1.20 (d) of \$130.00 for submission of this Terminal Disclaimer. A duplicate copy of this correspondence is enclosed to facilitate charging of the fee.

Respectfully Submitted,

Ku/hw = (

Signature

Richard S. Echler, Sr.

R & GAMBLE COMPANY

Typed or Printed Name Registration No. 41,006

(513) 622-1973

Date: November 9, 2005 Customer No. 27752 (Trmadisc.doc) (Last revised 11/5/2004)